bpc 157 multiple sclerosis clinical trial humans bpc-157 BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges Frontiers | Stable Gastric Pentadecapeptide

It does not rebuild tissue on its own

These results indicate modest efficacy, with realistic expectations being 0.25-0.5 kg (0.5-1 pound) per week under optimal conditions

Studies & References 1

At Healthspan, the AMPK Blend is designed to support the AMPK pathway that MOTS-c activates using compounds with a stronger evidence base in humans, including berberine and other AMPK-activating nutrients and is a clinically relevant starting point for women focused on insulin sensitivity and metabolic optimization

Secretary Kennedy has made no secret of his support for the molecules, saying he has used some of them himself and would like the FDA which is overseen by the Department of Health and Human Services to allow compounding pharmacies to again offer the drugs